Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy

Familial Cancer

Volumn 11, Issue 1, 2012, Pages 69-75

  Cohen, J V ^a   Chiel, L ^b   Boghossian, L ^b   Jones, M ^b   Stopfer, J E ^b   Powers, J ^b   Rebbeck, T R ^b   Nathanson, K L ^b   Domchek, S M ^b  

^a PENNSYLVANIA HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; Non cancer endpoints; Osteopenia; Osteoporosis

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE MUTATION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MEDICAL RECORD; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SALPINGOOOPHORECTOMY; SURGICAL RISK;

ADULT; AGED; AGED, 80 AND OVER; BONE DISEASES, METABOLIC; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HETEROZYGOTE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOTHYROIDISM; MEDICAL RECORDS; MIDDLE AGED; MUTATION; MYOCARDIAL INFARCTION; OSTEOPOROSIS; OVARIAN NEOPLASMS; OVARIECTOMY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR;

EID: 84858298100     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-011-9480-8     Document Type: Article

References (33)

1. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643-646. doi:10.1126/science.1088759 (Pubitemid 37310920)
2. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20): 1401-1408. doi:10.1056/NEJM199705153362001
3. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25(11):1329-1333. doi: 10.1200/JCO.2006.09.1066
4. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676-689 (Pubitemid 28164626)
5. Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10):1301-1308. doi: 10.1054/bjoc.2000.1407
6. Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K (2002) Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8(12):3776-3781 (Pubitemid 35424769)
7. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon- Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91(17):1475-1479 (Pubitemid 29424552)
8. Rebbeck TR (2002) Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 38(Suppl 6):S15-S17
9. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K (2002) Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609-1615. doi:10.1056/NEJMoa020119
10. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296(2):185-192. doi:10.1001/jama.296.2.185
11. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH (2005) Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 23(34):8629-8635. doi: 10.1200/JCO.2005.02.9199
12. Chang-Claude J, Andrieu N, Rookus M, Brohet R, Antoniou AC, Peock S, Davidson R, Izatt L, Cole T, Nogues C, Luporsi E, Huiart L, Hoogerbrugge N, Van Leeuwen FE, Osorio A, Eyfjord J, Radice P, Goldgar DE, Easton DF (2007) Age at menarche and menopause and breast cancer risk in the international BRCA1/2 carrier cohort study. Cancer Epidemiol Biomarkers Prev 16(4):740-746. doi:10.1158/1055-9965.EPI-06-0829
13. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23(30):7491-7496. doi:10.1200/JCO.2004.00.7138
14. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331-1337. doi:1200/JCO.2007.13.9626
15. Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S, Tucker MA, Struewing JP, Hartge P (2003) Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli populationbased case-control study. J Natl Cancer Inst 95(14):1072-1078 (Pubitemid 36950111)
16. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson GE, Van't Veer L, Lynch HT, Olopade OI, Weber BL, Rebbeck TR (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7(3):223-229. doi:10.1016/S1470-2045(06) 70585-X
17. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967-975. doi:10.1001/jama.2010.1237
18. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7(10):821-828. doi:10.1016/S1470-2045(06)70869-5 (Pubitemid 44464065)
19. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 113(5): 1027-1037. doi:10.1097/AOG.0b013e3181a11c64
20. Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80-87. doi:10.1093/jnci/djn442
21. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616-1622. doi:10.1056/NEJMoa012158
22. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23(28):6890-6898. doi:10.1200/ JCO.2005.02.626
23. Michelsen TM, Dorum A, Dahl AA (2009) A controlled study of mental distress and somatic complaints after risk-reducing salpingo- oophorectomy in women at risk for hereditary breast ovarian cancer. Gynecol Oncol 113(1):128-133. doi:10.1016/ j.ygyno.2008.12.024
24. Melton LJ 3rd, Crowson CS, Malkasian GD, O'Fallon WM (1996) Fracture risk following bilateral oophorectomy. J Clin Epidemiol 49(10):1111-1115 (Pubitemid 26348607)
25. Melton LJ 3rd, Khosla S, Malkasian GD, Achenbach SJ, Oberg AL, Riggs BL (2003) Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 18(5):900-905. doi: 10.1359/jbmr.2003.18.5.900 (Pubitemid 37294974)
26. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ 3rd (2007) Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69(11):1074-1083. doi:10.1212/01.wnl.0000276984.19542.e6 (Pubitemid 47517552)
27. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS (2005) Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 106(2):219-226. doi:10.1097/01 .AOG.0000167394.38215.56
28. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297(13):1465-1477. doi:10.1001/jama.297.13.1465
29. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK (2006) The impact of hormone replacement therapy on menopausal symptoms in younger highrisk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24(22):3576-3582. doi:10.1200/JCO.2005.05.1896 (Pubitemid 46630529)
30. Parker WH, Jacoby V, Shoupe D, Rocca W (2009) Effect of bilateral oophorectomy on women's long-term health. Womens Health (Lond Engl) 5(5):565-576. doi:10.2217/whe.09.42
31. Michelsen TM, Pripp AH, Tonstad S, Trope CG, Dorum A (2009) Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. Eur J Cancer 45(1): 82-89. doi:10.1016/j.ejca.2008.09.028
32. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 23(31):7804-7810. doi:10.1200/JCO.2004.00.8151 (Pubitemid 46657377)
33. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA (2008) Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100(19): 1361-1367. doi:10.1093/jnci/djn313